KUKU

KU ScholarWorks

  • myKU
  • Email
  • Enroll & Pay
  • KU Directory
    • Login
    View Item 
    •   KU ScholarWorks
    • Dissertations and Theses
    • Dissertations
    • View Item
    •   KU ScholarWorks
    • Dissertations and Theses
    • Dissertations
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Development of theranostics nanomaterials

    Thumbnail
    View/Open
    Yang_ku_0099D_13782_DATA_1.pdf (22.96Mb)
    Issue Date
    2014-12-31
    Author
    Yang, Qiuhong
    Publisher
    University of Kansas
    Format
    286 pages
    Type
    Dissertation
    Degree Level
    Ph.D.
    Discipline
    Pharmaceutical Chemistry
    Rights
    Copyright held by the author.
    Metadata
    Show full item record
    Abstract
    Clinical outcomes of conventional anticancer therapies are often compromised due to off-target toxicity and adaptive drug resistance. Moreover, currently there are no imaging modalities that can be utilized for real-time monitoring of therapeutic responses in the human body. Therefore, there is a critical need to develop a novel generation of personalized medicine that combines functionalities of diagnosis and therapy, with an ultimate goal of early detection, accurate treatment and timely assessment of therapeutic efficacy. Over the last few decades, a variety of nano-medical materials or devices such as liposomes, micelles, quantum dots, magnetic nanoparticles and plasmonic nanobubbles have been developed to deliver therapeutic products or diagnostic agents to the sites of disease in a controlled manner with reduced or eliminated side effects to normal tissues. This dissertation focuses on the development of functional molecular imaging probe and nanoparticles-based therapeutic agent delivery systems for effective theranostics of lymphatically metastatic cancer, thus opening new avenues to combat cancer. In chapter 2, a near-infrared (NIR) absorbing dye -based caspase-9 image probe was synthesized in 11 steps to directly detect apoptotic cells with high specificity. This cell-permeable molecular contrast agent has demonstrated the feasibility of monitoring cancer cell apoptosis induced by chemotherapeutics in mice bearing head and neck squamous cell carcinoma (HNSCC), via non-invasive photoacoustic imaging (PAI) within 24 h after treatment, thus to predict treatment efficacy. In chapter 3, a biocompatible core/shell FePt@Fe3O4 magnetic nanoparticles (MNPs) was developed as a robust probe for magnetic resonance imaging (MRI) and to mediate hyperthermia treatment against breast tumor. Enhanced anti-tumor effectiveness was demonstrated in a mouse model of 4T1.2 Neu breast tumor as a consequence of the high magnetic-thermal energy transfer capability of MNPs. In addition, increased MRI contrast in the tumor region potentiated the clinical application of MNPs for cancer diagnosis. In chapter 4, Cabozantinib (XL-184), a poorly water-soluble pan-kinase inhibitor, was encapsulated into a DSPE-PEG2000 micellar formulation with excellent colloidal stability. Compared with the free XL-184 solution, drug-loaded micelles exhibited increased intracellular drug uptake and higher cytotoxicity in one human lung adenocarcinoma epithelial cell line and two human malignant glioblastoma cell lines. In chapter 5, a high molecular-weight hyaluronic acid-deferoxamine (DFO) conjugated was synthesized for sustained release delivery of DFO, whose potent iron-chelating capability can be utilized to reverse the radiotherapy-induced pathologic effects. The HA-DFO conjugate exhibited significantly decreased cytotoxicity to normal cells and excellent biodegradability. In addition, localized HA- DFO injection stimulated vascularity and improved bony regeneration and union after radiotherapy. In chapter 6, a nano-hyaluronic acid (HA)-based anticancer drug, HA- Cisplatin, was subcutaneously injected in an in-vivo murine model for locally advanced melanoma. Compared with the untreated control group and cisplatin- treated group (intravenous or subcutaneous injection), significant tumor shrinkage was observed in the subcutaneous peri-tumoral HA-cisplatin group, offering great potential as a therapeutic option in the treatment of certain types of human melanoma.
    URI
    http://hdl.handle.net/1808/21651
    Collections
    • Pharmaceutical Chemistry Dissertations and Theses [141]
    • Dissertations [4473]

    Items in KU ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.


    We want to hear from you! Please share your stories about how Open Access to this item benefits YOU.


    Contact KU ScholarWorks
    785-864-8983
    KU Libraries
    1425 Jayhawk Blvd
    Lawrence, KS 66045
    785-864-8983

    KU Libraries
    1425 Jayhawk Blvd
    Lawrence, KS 66045
    Image Credits
     

     

    Browse

    All of KU ScholarWorksCommunities & CollectionsThis Collection

    My Account

    LoginRegister

    Statistics

    View Usage Statistics

    Contact KU ScholarWorks
    785-864-8983
    KU Libraries
    1425 Jayhawk Blvd
    Lawrence, KS 66045
    785-864-8983

    KU Libraries
    1425 Jayhawk Blvd
    Lawrence, KS 66045
    Image Credits
     

     

    The University of Kansas
      Contact KU ScholarWorks
    Lawrence, KS | Maps
     
    • Academics
    • Admission
    • Alumni
    • Athletics
    • Campuses
    • Giving
    • Jobs

    The University of Kansas prohibits discrimination on the basis of race, color, ethnicity, religion, sex, national origin, age, ancestry, disability, status as a veteran, sexual orientation, marital status, parental status, gender identity, gender expression and genetic information in the University’s programs and activities. The following person has been designated to handle inquiries regarding the non-discrimination policies: Director of the Office of Institutional Opportunity and Access, IOA@ku.edu, 1246 W. Campus Road, Room 153A, Lawrence, KS, 66045, (785)864-6414, 711 TTY.

     Contact KU
    Lawrence, KS | Maps